Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68451 | 0.88 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL68450 | 0.88 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL969077 | 0.88 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4766284 | 0.83 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4772969 | 0.82 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7356326 | 0.81 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19867874 | 0.80 | CA1 (0.65) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19305318 | 0.80 | CA2 (0.65) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17724546 | 0.80 | CA2 (0.65) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL28603292 | 0.79 | CA1 (0.59) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660085-B1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-10-15 | — | — | EP | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | CA1 4861/4885CA2 3954/4885CA7 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.